Document Classification

Section Type: METHODS

Text: The patients were randomized to : Group 1, 86 patients with genotype non-1 and viraemia < 1, 000, 000 HCV genome equivalents/ml (GenEq/ml) treated with 3 Million Units (MU) IFN three times weekly (t. i. w.) for 1 year ; Group 2, 42 patients with genotype 1 and viraemia < 1, 000, 000 GenEq / ml treated with 3 MU IFN t. i. w. for 1 year ; Group 3, 46 patients with genotype 1 and viraemia < 1, 000, 000 GenEq / ml treated with 5 MU IFN t. i. w. for 1 year ; Group 4, 85 patients with genotype non-1 and viraemia > 1, 000, 000 GenEq/ml treated with 3 MU IFN t. i. w. for 1 year ; Group 5, 88 patients with genotype non-1 and viraemia > 1, 000, 000 GenEq/ml treated with 5 MU IFN t. i. w. for 1 year ; Group 6, 94 patients with genotype 1 and viraemia > 1, 000, 000 GenEq/ml treated with 3 MU IFN t. i. w. for 1 year ; Group 7, 97 patients with genotype 1 and viraemia > 1, 000, 000 GenEq/ml treated with 5 MU IFN daily for 2 months followed by 5 MU t. i. w. for a further 10 months.